Notable events for Zimmer Biomet Holdings (ZBH) include its participation in Citi's 2024 Global Healthcare Conference as well as the Jefferies London Healthcare Conference. ZBH has also secured FDA clearances for its breakthrough Metal-Sensitive Knee Implant Technology and the Oxford® Cementless Partial Knee. Positive stock performance has been observed despite concurrent losses, with entities like Fmr LLC boosting their holdings. However, it has also been perceived as an underperforming stock on certain days.
Financial results for ZBH for Q3 2024 had been announced, with strong revenue growth. Despite these promising results, the company's stock has lost 21% over the last five years. Other pivotal moments include ZBH's acquisition agreement with OrthoGrid Systems, Inc., its partnership with Arnold Schwarzenegger who joins as Chief Movement Officer, and the launch of the Z1 Hip System in collaboration with NeuroOne.
In addition, ZBH has earned the distinction of having its Knee Revision System gain the CE Mark for European Expansion, and unexpected hit to 2024 Sales. Despite earning nods from regulatory bodies for various knee systems, the company has also been met with challenges, including software switch impact to the stock, and Q3 earnings estimates miss.
Zimmer Biomet Holdings ZBH News Analytics from Thu, 08 Feb 2024 08:00:00 GMT to Sat, 07 Dec 2024 16:09:31 GMT - Rating 4 - Innovation 6 - Information 8 - Rumor -2
